Bristol Myers Squibb's Mezigdomide Slashes Progression Risk by 52% in Late-Stage Myeloma Trial
Event summary
- Bristol Myers Squibb's mezigdomide (MeziKd) reduced risk of disease progression or death by 52% vs. standard care in relapsed/refractory multiple myeloma (RRMM).
- Phase 3 SUCCESSOR-2 trial showed median PFS of 18 months for MeziKd vs. 8.3 months for standard care (HR: 0.48; p<0.0001).
- Overall response rate was 80.2% for MeziKd vs. 53.4% for standard care, with 26.7% achieving complete response or better.
- Results presented at 2026 ASCO Annual Meeting; regulatory filings planned.
The big picture
Bristol Myers Squibb's success with mezigdomide validates its targeted protein degradation platform, potentially expanding treatment options for RRMM patients. The 52% reduction in progression risk positions the drug as a potential new standard of care, addressing a critical unmet need in later-line myeloma therapy. This follows a broader industry trend toward precision oncology approaches leveraging protein degradation technologies.
What we're watching
- Regulatory Pathway
- Whether Bristol Myers Squibb can secure expedited approval for mezigdomide given the strong PFS data.
- Commercial Potential
- The pace at which MeziKd could displace existing RRMM treatments if approved.
- Pipeline Validation
- How these results position Bristol Myers Squibb's targeted protein degradation platform in oncology.
Related topics